David Collier - Chief Executive Officer @ X-37

Overview

CB Rank (Investor)

David Collier is the Chief Executive Officer at X-37. He attended The Wharton School.

Number of Partner Investments

Announced Date	Organization Name	Investor Name	Lead Investor	Funding Round	Money Raised
obfuscated obfuscation	SurgiQuest	Presidio Partners	No	Series D - SurgiQuest	obfuscated obfuscation
obfuscated obfuscation	Ardelyx	CMEA Capital	No	Series B - Ardelyx	obfuscated obfuscation
obfuscated obfuscation	SurgiQuest	Presidio Partners	No	Series C - SurgiQuest	obfuscated obfuscation
obfuscated obfuscation	Ardelyx	CMEA Capital	Yes	Series A - Ardelyx	obfuscated obfuscation

Number of Current Jobs

Number of Past Jobs

has

current jobs including

Chief Executive Officer

CEO

, and

Director

. Additionally,

has had

past jobs including

Managing Director

Organization Name	Title At Company	Start Date	End Date
Burrill & Company	Managing Director	1997	Jul 2001
First Options of Chicago	Assistant Vice President	—	—
Magainin Pharmaceuticals Inc.	Consultant	—	—
Arthur D. Little	Consultant	—	—
CMEA Capital	Managing Director	Aug 2001	—

Number of Past Board & Advisor Roles

Organization Name	Title At Company	Start Date	End Date
VYNE Therapeutics	Board Member	Jun 2011	Oct 2017

Hub Name	CB Rank (Hub)
Alpha Intelligence Capital Portfolio Companies	93,939
DCVC Bio Portfolio Companies	87,067
Pharmaceutical Early Stage Companies With Less Than $500M in Revenue	55,776
Pharmaceutical Early Stage Companies With Less Than $1B in Revenue	55,593
Health Care Early Stage Companies With Less Than $10M in Revenue	32,170
Health Care Early Stage Companies With Fewer Than 10 Employees	54,403
West Coast Pharmaceutical Companies	20,857
San Francisco Bay Area Pharmaceutical Companies	45,125
Pharmaceutical Early Stage Companies With Less Than $10M in Revenue	64,049
West Coast Health Care Companies with Early Stage Venture Funding	61,386

studied at

and